These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38458402)

  • 1. In-situ forming biodegradable implants for sustained Fluocinolone acetonide release to the posterior eye: In-vitro and in-vivo investigations in rabbits.
    Karimi M; Abrishami M; Farzadnia M; Kamali H; Malaekeh-Nikouei B
    Int J Pharm; 2024 Apr; 654():123973. PubMed ID: 38458402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.
    Mruthyunjaya P; Khalatbari D; Yang P; Stinnett S; Tano R; Ashton P; Guo H; Nazzaro M; Jaffe GJ
    Arch Ophthalmol; 2006 Jul; 124(7):1012-8. PubMed ID: 16832025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period.
    Driot JY; Novack GD; Rittenhouse KD; Milazzo C; Pearson PA
    J Ocul Pharmacol Ther; 2004 Jun; 20(3):269-75. PubMed ID: 15279731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.
    Jaffe GJ; Yang CH; Guo H; Denny JP; Lima C; Ashton P
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3569-75. PubMed ID: 11006254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.
    Campochiaro PA; Hafiz G; Shah SM; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane F;
    Ophthalmology; 2010 Jul; 117(7):1393-9.e3. PubMed ID: 20202684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits.
    Kane FE; Green KE
    J Ocul Pharmacol Ther; 2015 Feb; 31(1):11-6. PubMed ID: 25562126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable, in situ forming poly(propylene fumarate)-based ocular drug delivery systems.
    Ueda H; Hacker MC; Haesslein A; Jo S; Ammon DM; Borazjani RN; Kunzler JF; Salamone JC; Mikos AG
    J Biomed Mater Res A; 2007 Dec; 83(3):656-66. PubMed ID: 17514745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers.
    Haesslein A; Ueda H; Hacker MC; Jo S; Ammon DM; Borazjani RN; Kunzler JF; Salamone JC; Mikos AG
    J Control Release; 2006 Aug; 114(2):251-60. PubMed ID: 16872709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
    Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
    Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.
    De Paiva MRB; Lage NA; Guerra MCA; Mol MPG; Ribeiro MCS; Fulgêncio GO; Gomes DA; Da Costa César I; Fialho SL; Silva-Cunha A
    Doc Ophthalmol; 2019 Feb; 138(1):3-19. PubMed ID: 30456454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results.
    Jaffe GJ; Foster CS; Pavesio CE; Paggiarino DA; Riedel GE
    Ophthalmology; 2019 Apr; 126(4):601-610. PubMed ID: 30367884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
    Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
    Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
    Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
    Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Nanofibrous Ocular Insert for Retinal Delivery of Fluocinolone Acetonide.
    Singla J; Bajaj T; Goyal AK; Rath G
    Curr Eye Res; 2019 May; 44(5):541-550. PubMed ID: 30577701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants.
    Campochiaro PA; Nguyen QD; Hafiz G; Bloom S; Brown DM; Busquets M; Ciulla T; Feiner L; Sabates N; Billman K; Kapik B; Green K; Kane FE;
    Ophthalmology; 2013 Mar; 120(3):583-587. PubMed ID: 23218184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained-release fluocinolone acetonide intravitreal insert for macular edema: clinical pharmacology and safety evaluation.
    Sadiq MA; Agarwal A; Soliman MK; Hanout M; Sarwar S; Do DV; Nguyen QD
    Expert Opin Drug Saf; 2015 Jul; 14(7):1147-56. PubMed ID: 25994877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
    Sanford M
    Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY.
    Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S
    Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis.
    Testi I; Pavesio C
    Ther Deliv; 2019 Oct; 10(10):621-625. PubMed ID: 31663454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.